Citi sees Exact Sciences shares climbing after rivals data disappoints By Investing.com Citi sees Exact Sciences shares climbing after rivals data disappoints…
Exact Sciences (EXAS) Oncoguard Esophagus Test Looks Promising Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…
Exact Sciences (EXAS) BLUE-C Study Results Published in NEJM Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…
Cathie Wood Darling Could Pop On Its Next-Gen Colon Cancer Test Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…
5 Small Biotech ETFs to Watch (Updated 2024) Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…